Kite secures third approved cell therapy indication in Europe

By Jane Byrne contact

- Last updated on GMT

© GettyImages/acilo
© GettyImages/acilo

Related tags: Kite, Gilead, CAR-T, Yescarta, Cell therapy

The European Commission (EC) has approved Kite’s CAR T-cell therapy, Yescarta, (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.

The move was anticipated given that, in April this year, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion in relation to Yescarta for that type of lymphoma.

It is the third approved indication for a Kite cell therapy in Europe. The treatment was already authorized by the EC for adult patients with relapsed or refractory diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma, after two or more lines of systemic therapy.

FL is the second most common type of lymphoma globally​ and accounts for about 22%​ of all lymphomas diagnosed worldwide. In Europe, about 27,000 new cases are diagnosed each year. 

Critical data 

The EU approval is supported by data from the pivotal, single-arm Phase 2 ZUMA-5 international study in patients with relapsed or refractory FL who had received at least two prior lines of systemic therapy, including the combination of an anti-CD20 monoclonal antibody and an alkylating agent.

FL that has relapsed multiple times is a difficult-to-treat disease with an especially poor prognosis​ as only 20% of patients are still alive at five years after their second relapse, said Ibrahim Yakoub-Agha, head of the hematopoietic cell transplantation and cellular therapy unit at Lille University Hospital. He noted that 91% of patients in the ZUMA-5 study responded to axicabtagene ciloleucel after three or more prior lines of therapy, and more than half of these were still in response two years later. “This sign of durable remission is critical for patients who need options that can deliver long-term benefit.”

FL is often misunderstood as easy to treat or non life-threatening, even when it has reached a significantly advanced stage, according to Nicola Mendelsohn, founder and chair of the Follicular Lymphoma Foundation (FLF). For patients with later-line relapsed or refractory disease, it is often very aggressive, she said. "Axicabtagene ciloleucel represents an important advance for a patient population in Europe with limited treatment options.” 

Manufacturing sites

Based in Santa Monica, California, Kite, which is owned by Gilead, has manufacturing operations in both North America and Europe.

The company received approval in June 2020​ from the EMA for the manufacture of Yescarta from its facility near Amsterdam, in the Netherlands. That site is expected to facilitate treatment​ for up to 4,000 patients per year. 

Related news

Show more

Related product

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us

Products

View more

Webinars